您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 眼科药物->治疗青光眼药物
处方药:处方药
包装规格: 0.3毫升30支
计价单位:
   
生产厂家英文名:
Santen
该药品相关信息网址1:
http://drugdelivery.pharmaceutical-business-review.com/news/santen-pharmaceutical-introduces-tapros-mini-ophthalmic-solution-111013
原产地英文商品名:
Tapros Mini ophthalmic solution 0.0015% 0.3ml 30 sticks (cold chain product)
原产地英文药品名:
Tafluprost
中文参考商品译名:
Tapros 迷你滴眼液0.0015% 0.3毫升30支 (冷凍产品)
中文参考药品译名:
他氟前列素
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
glaucoma
英文适应病症2:
ocular hypertension
临床试验期:
完成
中文适应病症参考翻译1:
青光眼
中文适应病症参考翻译2:
高眼压症
药品信息:
参天制药,眼科和抗风湿药的制造商,已经推出TAPROS MINI滴眼液0.0015%,青光眼和高眼压症表示。 SANTEN TAPROS MINI眼用溶液含有前列腺素F2a类似物他氟前列素作为有效成分。 的不含防腐剂的TAPROS MINI具有相同的他氟前列素的浓度如在TAPROS滴眼液0.0015%,它提供了等效的降低眼内压的效果原始TAPROS。 TAPROS滴眼液已经合作开发的参天制药和旭硝子并于2008年推出。 参天制药收到了日本厚生劳动省的制造和销售审批在2013年1月该公司的TAPROS迷你滴眼液0.0015%。 该公司预计,TAPROS MINI药物将有助于通过提供医疗保健专业人员更广泛的治疗方案改善患者的生活质量。 参天制药主要从事眼科领域,并已经销售几种类型的青光眼药物。 新药可在每0.3毫升瓶JPY96.9的价格。 目前,前列腺素F2α类似物已经被最常用的处方用于治疗青光眼和高眼压症的治疗。 青光眼是视力障碍,如视力丧失的主要原因,如果不及时治疗甚至可能导致失明。 异常升高的眼内压是用于青光眼的最重要的危险因素,它的特征在于视神经损伤和视野损失。 Santen Pharmaceutical, a manufacturer of ophthalmic and anti-rheumatic pharmaceuticals, has introduced TAPROS MINI ophthalmic solution 0.0015%, indicated for glaucoma and ocular hypertension. SANTEN TAPROS MINI ophthalmic solution contains prostaglandin F2a analogue tafluprost as active ingredient. The preservative-free TAPROS MINI has the same tafluprost concentration as in TAPROS ophthalmic solution 0.0015% and it provides equivalent intraocular pressure-reducing effect as original TAPROS. TAPROS ophthalmic solution has been co-developed by Santen Pharmaceutical and Asahi Glass and was launched in 2008. Santen Pharmaceutical received the Japanese Ministry of Health, Labour and Welfare's manufacturing and marketing approval for the company's TAPROS Mini Ophthalmic Solution 0.0015% in January 2013. The company anticipates that the TAPROS MINI drug will help improve the quality of life of patients by giving health care professionals a wider range of treatment options. Santen Pharmaceutical is primarily engaged in the ophthalmic field and already markets several types of glaucoma drugs. The new drug is available at a price of JPY96.9 per 0.3ml bottle. Currently, prostaglandin F2a analogues have been most commonly prescribed for the treatment of glaucoma and ocular hypertension. Glaucoma is the major cause of visual impairments such as loss of vision, and if left untreated it may even lead to blindness. Abnormally elevated intraocular pressure is the most important risk factor for glaucoma and it is characterized by optic nerve damage and progressive visual field loss.
更新日期: 2014-06-25
附件:
201471323395633.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com